Background: Nowadays, chronic obstructive pulmonary disease (COPD) is one of the most common diseases that cause morbidity and mortality. The prediction of survival for acute exacerbation of COPD (AECOPD) is substantial for the management of those patients in the emergency room (ER). Aim: The main objectives of this study were to determine which clinical or laboratory parameters, including vital signs, number of hospitalizations, lactate clearance, C-reactive protein/albumin ratio (CAR), procalcitonin, platelet/lymphocyte ratio, and neutrophil/lymphocyte ratio were the most useful predictors of the 30 day mortality for AECOPD in the ER. Materials and Methods: The study took place at Kars Harakani State Hospital. The files of patients were evaluated retrospectively. Results: The study included 243 patients and 15.6% of those died within 30 days. The mean systolic blood pressure (SBP) was lower in those with who survived (P = 0.008). The hospitalization in intensive care unit (HICU) during the past 12 months (P < 0.001), CAR (P = 0.044), and procalcitonin (P = 0.002) was higher and forced-vital capacity (FVC) (P = 0.035) was lower in nonsurvivors. The age, HICU, and procalcitonin level correlated positively (r = 0.188, P = 0.003; r = 0.400, P < 0.001; r = 0.223, P = 0.001) and SBP, FVC correlated negatively with 30-day mortality, respectively (r = −0.197, P = 0.002; r = 0.400, P = 0.034). Conclusions: Age, SBP, CAR, procalcitonin, HICU, and FVC are predictors for 30-day mortality in patients who admit to ER with AECOPD.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive, chronic, and inflammatory disease of lungs and airways, which is caused by noxious particles and smoke. [1, 2] Worldwide, COPD is one of the most common diseases that cause morbidity and mortality, and it is predicted that COPD will be the third-leading reason of death in 2020. [3] Exacerbations and frequent hospitalizations are the major risk factors for increased death due to COPD. [4] Acute exacerbation of COPD (AECOPD) is characterized by worsened respiratory symptoms such as dyspnea, productive cough, and increased nonrespiratory symptoms such as fever, malaise, and fatigue with acute onset. [5] Several recent studies have investigated the usefulness of various blood biomarkers for the prediction of prognosis and mortality of patients with AECOPD. Lactate clearance (LC) which is a measure of the change in the lactate levels during the therapy of critically ill patients, C-reactive protein/albumin ratio (CAR), neutrophil/ lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) are novel biomarkers for many systemic inflammatory diseases such as COPD. [6] [7] [8] [9] [10] The main objectives of this study were to determine which clinical or laboratory results, including vital signs, number of hospitalizations, LC, CAR, procalcitonin, PLR, and NLR, were the most useful predictors of the 30-day mortality in patients with AECOPD who admitted to the emergency room (ER).
MATERIALS AND METHODS

Patients and study design
This retrospective study was conducted with the approval of Kafkas University Medical Faculty Ethics Committee between June 2018 and April 2019. The study included 243 patients (93 females and 150 males) with AECOPD who admitted to ER, Stages I-IV, for all. Patients were included in the study if they met the following criteria: (a) primary clinical diagnosis of AECOPD, characterized as an acute worsening of respiratory symptoms such as dyspnea, cough, or sputum purulence and (b) COPD diagnosis supported by spirometric data of airflow obstruction even with bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7. For patients who were admitted to ER more than once during the study period, only the first admission data were recorded. Patients without all the laboratory results and vital signs or demographic profile were not evaluated. Patients who had primary diagnosis such as congestive heart failure, pneumonia, pleural effusion, pneumothorax, pulmonary embolism, cardiac ischemia, upper airway obstruction, asthma exacerbation, and any other reason of dyspnea were excluded from the study.
Data collection
Baseline characteristics, including age, gender, systolic blood pressure (SBP), fever, respiratory rate, peripheral oxygen saturation, smoking status, biomass exposure, and comorbidities such as hypertension, diabetes mellitus, congestive heart failure, prostate hyperplasia, obstructive sleep apnea, atrial fibrillation, chronic renal failure, coronary artery disease, hyperlipidemia, cancer, goiter; hospitalization rates due to AECOPD, including number of hospitalization in the intensive care unit during the past 12 months (NHICU), number of hospitalization in the respiratory diseases unit during the past 12 months, number of admission to the ER during the past 12 months, discharge time interval from the hospital, home support, including usage of BiPAP machine, portable oxygen concentrator and nebulizer, lung function tests, including FEV1 and FVC. The laboratory tests, including LC, CAR, procalcitonin, PLR, and NLR, were conducted within 24 h of ER admission. The primary outcome was 30-day all-cause mortality. The need for informed consent was waived given the retrospective design of the study.
LC is calculated as explained; LC = first lactate measured in ER admission-second lactate measured at 6 h × 100/First lactate measured in ER admission. A negative LC indicates increase of lactate after 6 h, whereas the positive LC shows decrease of lactate value. [8] 
Statistical analysis
All statistical calculations were performed with SPSS software version 21.0 (SPSS for Windows, Chicago, IL, USA). All continuous variables were expressed as mean, standard deviation, median, minimum, and maximum; categorical variables were defined as percentages (%). The categorical parameters were compared with the Chi-square test and Fisher's exact test. The normal distribution was determined by histogram and Kolmogorov-Smirnov test. In the comparison of two independent groups, t-test was used when the parametric conditions were provided, and the Mann-Whitney U-test was used when it was not provided. A nonparametric (distribution free) test known as Spearman's rank correlation coefficients were used to measure the strength of the associations between two variables. All tests were applied as two tailed; the statistical significance level was P < 0.05 and P < 0.01. 2 demonstrates the relationship between 30-day mortality and results of patients in the ER. The mean age of patients who died within 30 days was greater than those who survived (P = 0.002). The mean SBP was lower in those with who survived (P = 0.008). The NHICU (P < 0.001), CAR (P = 0.044), and procalcitonin (P = 0.002) were higher and FVC (P = 0.035) was lower in patients who died within 30 days than those who survived.
RESULTS
Between
The age, NHICU, and procalcitonin level correlated with 30-day mortality, respectively (r = 0.188, P = 0.003; r = 0.400, P < 0.001; r = 0.223, P = 0.001). SBP and FVC correlated negatively with 30-day mortality, respectively (r = −0.197, P = 0.002; r = 0.400, P = 0.034). Table 3 ].
DISCUSSION
AECOPD is an acute manifestation during the clinical course of COPD, and this presentation is related to decrease of lung function and increase of mortality in COPD patients. [6] Prediction of mortality with a basic and safe biomarker method or clinical finding that can evaluate the survival during AECOPD admission to ER is important for the management of patients. In this study, the age correlated expectedly with 30-day mortality and nonsurvivor patients were older than survivors. FVC of nonsurvivor patients was inversely correlated with mortality. Pulmonary functions known as FEV1 and FVC, which is measured by spirometry is a significant indicator of morbidity and mortality in elderly age groups. As people get older, their total lung capacity decreases and the higher frequency of comorbidities making elderly patients more vulnerable to death. [3, 11, 12] In this study, we observed that SBP measured at admission to ER was lower for nonsurvivor patients, and it was correlated inversely with mortality. It is known that the SBP increases with age, but a decrease occurs after the age of 70-80 years. [13] High blood pressure is a well-known risk factor for mortality from vascular diseases, but several studies have reported and suggested that lower SBP may also increase the mortality and morbidity from vascular diseases, primarily among elderly patients with vascular diseases or any other comorbidity. Nowadays, the relationship between low SBP and vascular diseases remain ill-defined. [13] [14] [15] [16] Low-SBP may cause inadequate perfusion to vital organs such as the brain and heart so that low pressure can increase the risk of mortality.
Our study confirms that CAR and procalcitonin were higher in nonsurvivors and procalcitonin correlated with 30-day mortality. C-reactive protein, albumin, CAR, and procalcitonin are biomarkers used for measure and predict of mortality, morbidity, and prognosis in systemic inflammatory diseases such as COPD. [9, 10] Table 3 presents the relationship between gender, hospitalization time unit, LC, and 30-day mortality estimate the severity and mortality rate of patients suffer from COPD. [9, 10, 17, 18] Most of the survivors (80%) discharged from hospital <7 days and NHICU were higher in nonsurvivors. Some other studies suggest that the duration of hospitalization and hospitalization during the past several months were associated with patients who died after exacerbation of COPD. [19, 20] Severity of COPD, older age, severity of dyspnea, increased number of comorbidities, and inadequate home support for geriatric patients may cause prolongation of hospitalization duration in the ICU.
Retrospective design of the study, use of all-cause mortality, as opposed to specific causes and single center are limitations of this study.
CONCLUSIONS
To sum up, older age, lower SBP, increased CAR and procalcitonin, HICU, and FVC may predict 30-day mortality in patients who admit to ER with AECOPD.
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